Background: Youth-onset type 2 diabetes (T2D) is increasing in many countries, creating large personal and societal burdens. While many primary health-care professionals (HCPs) are aware of the classic symptoms of T2D, there are several other manifestations that could indicate its presence. Summary: This narrative review summarizes information on these symptoms and indicators, focusing on those less well known. The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annulare, necrobiosis lipoidica diabeticorum, and scleredema), gynecological (e.g., polycystic ovary syndrome, oligomenorrhea, and vulvovaginitis), hepatological (e.g., nonalcoholic fatty liver disease), and psychiatric diseases (e.g., psychosis, depression, and autism) could indicate that a patient has T2D or is at increased risk of T2D. Other less well-known indicators include abnormal blood tests (e.g., oxidized lipids, inflammation markers, hepatokines, and adipokines), prescriptions for antipsychotic medications or statins, and disrupted sleep patterns. Key Message: Due to the diversity of T2D manifestations in young people, primary HCPs need to remain alert to its possible presence.

Keywords:
Youth-onset type 2 diabetes, Pediatrics, Dermatology, Gynecology, Hepatology
1.
International Diabetes Federation. IDF Diabetes Atlas. 2017. Available from: http://www.diabetesatlas.org/ (accessed 11th June 2018).
2.
Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities.
Diabetes Care
. 2016 Sep;39(9):1635–42.
3.
Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al.; SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012.
N Engl J Med
. 2017 Apr;376(15):1419–29.
4.
Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.
Ann N Y Acad Sci
. 2015 Sep;1353:113–37.
5.
Hood KK, Beavers DP, Yi-Frazier J, Bell R, Dabelea D, Mckeown RE, et al. Psychosocial burden and glycemic control during the first 6 years of diabetes: results from the SEARCH for Diabetes in Youth study.
J Adolesc Health
. 2014 Oct;55(4):498–504.
6.
Donaghue KC, Marcovecchio ML, Wadwa RP, Chew EY, Wong TY, Calliari LE, et al. ISPAD Clinical Practice Consensus Guidelines 2018: microvascular and macrovascular complications in children and adolescents.
Pediatr Diabetes
. 2018 Oct;19(Suppl 27):262–74.
7.
Kumar AR, Kaplowitz PB. Patient age, race and the type of diabetes have an impact on the presenting symptoms, latency before diagnosis and laboratory abnormalities at time of diagnosis of diabetes mellitus in children.
J Clin Res Pediatr Endocrinol
. 2009;1(5):227–32.
8.
Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, Reinehr T, Tandon N, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth.
Pediatr Diabetes
. 2018 Oct;19(Suppl 27):28–46.
9.
Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents.
Pediatr Diabetes
. 2018 Oct;19(Suppl 27):7–19.
10.
Reynolds K, Liese AD, Anderson AM, Dabelea D, Standiford D, Daniels SR, et al. Prevalence of tobacco use and association between cardiometabolic risk factors and cigarette smoking in youth with type 1 or type 2 diabetes mellitus.
J Pediatr
. 2011 Apr;158(4):594–601.e1.
11.
Wittmeier KD, Wicklow BA, MacIntosh AC, Sellers EA, Ryner LN, Serrai H, et al. Hepatic steatosis and low cardiorespiratory fitness in youth with type 2 diabetes.
Obesity (Silver Spring)
. 2012 May;20(5):1034–40.
12.
Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al.; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline.
J Clin Endocrinol Metab
. 2011 Jan;96(1):159–67.
13.
Sellers EA, Dean HJ, Shafer LA, Martens PJ, Phillips-Beck W, Heaman M, et al. Exposure to gestational diabetes mellitus: impact on the development of early-onset type 2 diabetes in Canadian first nations and non-first nations offspring.
Diabetes Care
. 2016 Dec;39(12):2240–6.
14.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018.
Diabetes Care
. 2018 Jan;41(Suppl 1):S13–27.
15.
Urakami T, Suzuki J, Yoshida A, Saito H, Wada M, Takahashi S, et al. Prevalence of components of the metabolic syndrome in schoolchildren with newly diagnosed type 2 diabetes mellitus.
Pediatr Diabetes
. 2009 Dec;10(8):508–12.
16.
Abbasi A, Juszczyk D, van Jaarsveld CH, Gulliford MC. Body mass index and incident type 1 and type 2 diabetes in children and young adults: a retrospective cohort study.
J Endocr Soc
. 2017 Apr;1(5):524–37.
17.
Tanamas SK, Reddy SP, Chambers MA, Clark EJ, Dunnigan DL, Hanson RL, et al. Effect of severe obesity in childhood and adolescence on risk of type 2 diabetes in youth and early adulthood in an American Indian population.
Pediatr Diabetes
. 2018 Jun;19(4):622–9.
18.
Estrada E, Eneli I, Hampl S, Mietus-Snyder M, Mirza N, Rhodes E, et al.; Children’s Hospital Association. Children’s Hospital Association consensus statements for comorbidities of childhood obesity.
Child Obes
. 2014 Aug;10(4):304–17.
19.
Abraham C, Rozmus CL. Is acanthosis nigricans a reliable indicator for risk of type 2 diabetes in obese children and adolescents? A systematic review.
J Sch Nurs
. 2012 Jun;28(3):195–205.
20.
Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders.
Transl Pediatr
. 2017 Oct;6(4):300–12.
21.
Mendes AL, Miot HA, Haddad V. Diabetes mellitus and the skin.
An Bras Dermatol
. 2017 Jan-Feb;92(1):8–20.
22.
Davison JE, Davies A, Moss C, Kirk JM, Taibjee SM, Agwu JC. Links between granuloma annulare, necrobiosis lipoidica diabeticorum and childhood diabetes: a matter of time?
Pediatr Dermatol
. 2010 Mar-Apr;27(2):178–81.
23.
Carreau AM, Baillargeon JP. PCOS in adolescence and type 2 diabetes.
Curr Diab Rep
. 2015 Jan;15(1):564.
24.
Amed S, Hamilton JK, Sellers EA, Panagiotopoulos C, Hadjiyannakis S, Shah BR, et al. Differing clinical features in Aboriginal vs. non-Aboriginal children presenting with type 2 diabetes.
Pediatr Diabetes
. 2012 Sep;13(6):470–5.
25.
Morrison JA, Glueck CJ, Daniels S, Wang P, Stroop D. Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years.
Metabolism
. 2011 Sep;60(9):1285–93.
26.
Kelsey MM, Braffett BH, Geffner ME, Levitsky LL, Caprio S, McKay SV, et al.; TODAY Study Group. Menstrual dysfunction in girls from the treatment options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
J Clin Endocrinol Metab
. 2018 Jun;103(6):2309–18.
27.
Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome.
J Pediatr
. 2001 Jan;138(1):38–44.
28.
Curran J, Hayward J, Sellers E, Dean H. Severe vulvovaginitis as a presenting problem of type 2 diabetes in adolescent girls: a case series.
Pediatrics
. 2011 Apr;127(4):e1081–5.
29.
Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease.
JAMA Pediatr
. 2016 Oct;170(10):e161971.
30.
Cioffi CE, Welsh JA, Cleeton RL, Caltharp SA, Romero R, Wulkan ML, et al. Natural history of NAFLD diagnosed in childhood: a single-center study.
Children (Basel)
. 2017 May;4(5):E34.
31.
Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.
Aliment Pharmacol Ther
. 2010 Feb;31(3):396–406.
32.
Chen HJ, Lee YJ, Yeh GC, Lin HC. Association of attention-deficit/hyperactivity disorder with diabetes: a population-based study.
Pediatr Res
. 2013 Apr;73(4 Pt 1):492–6.
33.
Chen MH, Lan WH, Hsu JW, Huang KL, Su TP, Li CT, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study.
Diabetes Care
. 2016 May;39(5):788–93.
34.
Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis.
JAMA Psychiatry
. 2016 Mar;73(3):247–59.
35.
Irving RR, Mills JL, Choo-Kang EG, McLaughlin W, Wright-Pascoe R, Morrison EY, et al. Diabetes and psychological co-morbidity in children with a family history of early-onset type 2 diabetes.
Int J Psychol
. 2008 Dec;43(6):937–42.
36.
Jensen KG, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, et al. Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial.
J Clin Psychiatry
. 2017 Sep/Oct;78(8):e1035–46.
37.
Kelly NR, Shomaker LB, Radin RM, Thompson KA, Cassidy OL, Brady S, et al. Associations of sleep duration and quality with disinhibited eating behaviors in adolescent girls at-risk for type 2 diabetes.
Eat Behav
. 2016 Aug;22:149-55.
38.
Wilfley D, Berkowitz R, Goebel-Fabbri A, Hirst K, Ievers-Landis C, Lipman TH, et al.; TODAY Study Group. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study.
Diabetes Care
. 2011 Apr;34(4):858–60.
39.
Schmidt F, Kapellen TM, Wiegand S, Herbst A, Wolf J, Fröhlich-Reiterer EE, et al.; DPV-Wiss Study Group; BMBF Competence Network Diabetes. Diabetes mellitus in children and adolescents with genetic syndromes.
Exp Clin Endocrinol Diabetes
. 2012 Nov;120(10):579–85.
40.
O’Gorman CS, Syme C, Lang J, Bradley TJ, Wells GD, Hamilton JK. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome.
Clin Endocrinol (Oxf)
. 2013 Jun;78(6):907–13.
41.
Stagi S, Lapi E, Cecchi C, Chiarelli F, D’Avanzo MG, Seminara S, et al. Williams-beuren syndrome is a genetic disorder associated with impaired glucose tolerance and diabetes in childhood and adolescence: new insights from a longitudinal study.
Horm Res Paediatr
. 2014;82(1):38–43.
42.
Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, et al. Effects of metreleptin in pediatric patients with lipodystrophy.
J Clin Endocrinol Metab
. 2017 May;102(5):1511–9.
43.
Levine RS. Obesity, diabetes and periodontitis–a triangular relationship?
Br Dent J
. 2013 Jul;215(1):35–9.
44.
Amutha A, Unnikrishnan R, Anjana RM, Mohan V. Prepubertal childhood onset type 2 diabetes mellitus: four case reports.
J Assoc Physicians India
. 2017 Feb;65(2):43–6.
45.
Aburawi EH, AlKaabi J, Zoubeidi T, Shehab A, Lessan N, Al Essa A, et al. Subclinical inflammation and endothelial dysfunction in young patients with diabetes: a study from United Arab Emirates.
PLoS One
. 2016 Jul;11(7):e0159808.
46.
Lipton RB, Drum ML, Danielson KK, Greeley SA, Bell GI, Hagopian WA. Onset features and subsequent clinical evolution of childhood diabetes over several years.
Pediatr Diabetes
. 2011 Jun;12(4 Pt 1):326–34.
47.
Marin MT, Dasari PS, Tryggestad JB, Aston CE, Teague AM, Short KR. Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers.
J Diabetes Complications
. 2015 Jul;29(5):679–85.
48.
Seyfarth J, Reinehr T, Hoyer A, Reinauer C, Bächle C, Karges B, et al. Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
J Inherit Metab Dis
. 2018 Jan;41(1):73–9.
49.
Levenson AE, Shah AS, Khoury PR, Kimball TR, Urbina EM, de Ferranti SD, et al. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.
Pediatr Diabetes
. 2017 Dec;18(8):755–60.
50.
Rempel JD, Packiasamy J, Dean HJ, McGavock J, Janke A, Collister M, et al. Preliminary analysis of immune activation in early onset type 2 diabetes.
Int J Circumpolar Health
. 2013 Aug;72(1):72.
51.
Reinehr T, Karges B, Meissner T, Wiegand S, Fritsch M, Holl RW, et al. Fibroblast growth factor 21 and fetuin-A in obese adolescents with and without type 2 diabetes.
J Clin Endocrinol Metab
. 2015 Aug;100(8):3004–10.
52.
Reinehr T, Karges B, Meissner T, Wiegand S, Stoffel-Wagner B, Holl RW, et al. Inflammatory markers in obese adolescents with type 2 diabetes and their relationship to hepatokines and adipokines.
J Pediatr
. 2016 Jun;173:131–5.
53.
Reinehr T, Woelfle J, Wiegand S, Karges B, Meissner T, Nagl K, et al. Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents.
Pediatr Diabetes
. 2016 Jun;17(4):281–8.
54.
Tryggestad JB, Wang JJ, Zhang SX, Thompson DM, Short KR. Elevated plasma pigment epithelium-derived factor in children with type 2 diabetes mellitus is attributable to obesity.
Pediatr Diabetes
. 2015 Dec;16(8):600–5.
55.
Al-Daghri NM, Al-Saleh Y, Aljohani N, Alokail M, Al-Attas O, Alnaami AM, et al. Vitamin D deficiency and cardiometabolic risks: a juxtaposition of Arab adolescents and adults.
PLoS One
. 2015 Jul;10(7):e0131315.
56.
Galhardo J, Hunt LP, Shield JP. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with acanthosis nigricans in obese adolescents.
Diabet Med
. 2012 Jul;29(7):e117–20.
57.
Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease.
Mutagenesis
. 2011 Jan;26(1):77–83.
58.
Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.
JAMA Psychiatry
. 2013 Oct;70(10):1067–75.
59.
Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study.
J Am Acad Child Adolesc Psychiatry
. 2014 Sep;53(9):971–979.e6.
60.
Burcu M, Zito JM, Safer DJ, Magder LS, dosReis S, Shaya FT, et al. Concomitant use of atypical antipsychotics with other psychotropic medication classes and the risk of type 2 diabetes mellitus.
J Am Acad Child Adolesc Psychiatry
. 2017 Aug;56(8):642–51.
61.
Sohn M, Talbert J, Blumenschein K, Moga DC. Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents.
Pharmacoepidemiol Drug Saf
. 2015 Jun;24(6):583–91.
62.
Burcu M, Zito JM, Safer DJ, Magder LS, ­dosReis S, Shaya FT, et al. Association of ­antidepressant medications with incident type 2 diabetes among Medicaid-insured youths.
JAMA Pediatr
. 2017 Dec;171(12):1200–7.
63.
Joyce NR, Zachariah JP, Eaton CB, Trivedi AN, Wellenius GA. Statin use and the risk of type 2 diabetes mellitus in children and adolescents.
Acad Pediatr
. 2017 Jul;17(5):515–22.
64.
Rudnicka AR, Nightingale CM, Donin AS, Sattar N, Cook DG, Whincup PH, et al. Sleep duration and risk of type 2 diabetes.
Pediatrics
. 2017 Sep;140(3):e20170338.
65.
Shalitin S, Tauman R, Meyerovitch J, Sivan Y. Are frequency and severity of sleep-disordered breathing in obese children and youth with and without type 2 diabetes mellitus different?
Acta Diabetol
. 2014 Oct;51(5):757–64.
66.
Rutter MK. Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes.
Diabetologia
. 2018 Sep;61:43-7.
67.
Kester LM, Hey H, Hannon TS. Using hemoglobin A1c for prediabetes and diabetes diagnosis in adolescents: can adult recommendations be upheld for pediatric use?
J Adolesc Health
. 2012 Apr;50(4):321–3.
68.
Bhagyanathan M, Dhayanithy D, Parambath VA, Bijayraj R. Acanthosis nigricans: A screening test for insulin resistance - An important risk factor for diabetes mellitus type-2.
J Family Med Prim Care
. 2017 Jan-Mar;6(1):43–6.
69.
Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase.
J Pediatr Gastroenterol Nutr
. 2005 Jul;41(1):94–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.